Abstract
Staphylococcus aureus is a leading causative agent in sepsis, endocarditis, and pneumonia. An emerging concept is that prognosis worsens when the infecting S. aureus strain has the capacity to not only colonize tissue as an extracellular pathogen, but to invade host cells and establish intracellular bacterial populations. In previous work, we identified host CDC42 as a central regulator of endothelial cell invasion by S. aureus. In the current work, we report that ML 141, a first-in-class CDC42 inhibitor, decreases invasion and resultant pathogenesis in a dose-dependent and reversible manner. Inhibition was found to be due in part to decreased remodeling of actin that potentially drives endocytic uptake of bacteria/fibronectin/integrin complexes. ML 141 decreased binding to fibronectin at these complexes, thereby limiting a key pathogenic mechanism used by S. aureus to invade. Structural analogs of ML 141 were synthesized (designated as the RSM series) and a subset identified that inhibit invasion through non-cytotoxic and non-bactericidal mechanisms. Our results support the development of adjunctive therapeutics targeting host CDC42 for mitigating invasive infection at the level of the host.
Keywords: CDC42, fibronectin, ML 141, MRSA, MSSA, pyrazolines, sepsis.
Current Pharmaceutical Biotechnology
Title:Small Molecule Inhibitors Limit Endothelial Cell Invasion by Staphylococcus aureus
Volume: 15 Issue: 8
Author(s): Diana Cordero, Christopher R. Fullenkamp, Rachel R. Pelly, Katie M. Reed, Lindy M. Caffo, Ashley N. Zahrt, Micaleah Newman, Sarah Komanapalli, Evan M. Niemeier, Derron L. Bishop, Heather A. Bruns, Mark K. Haynes, Larry A. Sklar, Robert E. Sammelson and Susan A. McDowell
Affiliation:
Keywords: CDC42, fibronectin, ML 141, MRSA, MSSA, pyrazolines, sepsis.
Abstract: Staphylococcus aureus is a leading causative agent in sepsis, endocarditis, and pneumonia. An emerging concept is that prognosis worsens when the infecting S. aureus strain has the capacity to not only colonize tissue as an extracellular pathogen, but to invade host cells and establish intracellular bacterial populations. In previous work, we identified host CDC42 as a central regulator of endothelial cell invasion by S. aureus. In the current work, we report that ML 141, a first-in-class CDC42 inhibitor, decreases invasion and resultant pathogenesis in a dose-dependent and reversible manner. Inhibition was found to be due in part to decreased remodeling of actin that potentially drives endocytic uptake of bacteria/fibronectin/integrin complexes. ML 141 decreased binding to fibronectin at these complexes, thereby limiting a key pathogenic mechanism used by S. aureus to invade. Structural analogs of ML 141 were synthesized (designated as the RSM series) and a subset identified that inhibit invasion through non-cytotoxic and non-bactericidal mechanisms. Our results support the development of adjunctive therapeutics targeting host CDC42 for mitigating invasive infection at the level of the host.
Export Options
About this article
Cite this article as:
Cordero Diana, Fullenkamp R. Christopher, Pelly R. Rachel, Reed M. Katie, Caffo M. Lindy, Zahrt N. Ashley, Newman Micaleah, Komanapalli Sarah, Niemeier M. Evan, Bishop L. Derron, Bruns A. Heather, Haynes K. Mark, Sklar A. Larry, Sammelson E. Robert and McDowell A. Susan, Small Molecule Inhibitors Limit Endothelial Cell Invasion by Staphylococcus aureus, Current Pharmaceutical Biotechnology 2014; 15 (8) . https://dx.doi.org/10.2174/1389201015666140909124310
DOI https://dx.doi.org/10.2174/1389201015666140909124310 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prevention of Ischemic Stroke: Antithrombotic Therapy in Cardiac Embolism
Current Drug Targets Nursing Assessment, Education, and Care of Extremely Premature Neonates with Patent Ductus Arteriosus
Current Pediatric Reviews Synthesis and Characterisation of Super-Paramagnetic Iron Oxide Nanoparticles (SPIONs) for Minimising <i>Aeromonas hydrophila</i> Load from Freshwater
Current Nanoscience Perceval Sutureless Valve – are Sutureless Valves Here?
Current Cardiology Reviews Thoracic Aortic Aneurysm: Blood Pressure and Inflammation as Key Factors in the Development of Aneurysm Dissection
Current Pharmaceutical Design Oral Factor Xa (FXa) Inhibitors for Treatment of Heparin-induced Thrombocytopenia (HIT)
Current Drug Therapy Coronary Artery Bypass Graft in HIV-Infected Patients: A Multicenter Case Control Study
Current HIV Research Kingella kingae: A Pediatric Pathogen of Increasing Importance
Current Pediatric Reviews A Review of Selected Adult Congenital Heart Diseases Encountered in Daily Practice
Current Cardiology Reviews Complementary Therapies in Inflammatory Bowel Diseases
Current Drug Targets Chromogranin A-Derived Peptides Are Involved in Innate Immunity
Current Medicinal Chemistry The Role of Hypoxia and Platelets in Air Travel-Related Venous Thromboembolism
Current Pharmaceutical Design Drugs in Pediatric Ischemic Stroke
Current Drug Targets New Treatments for Emerging Cystic Fibrosis Pathogens other than Pseudomonas
Current Pharmaceutical Design Valve Endothelial Cells – Not Just Any Old Endothelial Cells
Current Vascular Pharmacology Targeting RGD Recognizing Integrins: Drug Development, Biomaterial Research, Tumor Imaging and Targeting
Current Pharmaceutical Design Reducing the Development of Antibiotic Resistance in Critical Care Units
Current Pharmaceutical Biotechnology Preface
Recent Patents on Anti-Infective Drug Discovery The Evaluation and Management of Adult-Onset Henoch-Schonlein Purpura
Current Rheumatology Reviews The Role of 18F-FDG-PET/CT in Infectious Endocarditis and Cardiac Device Infection
Current Molecular Imaging (Discontinued)